Literature DB >> 199119

Assessment of the role of surgery for control of lung cancer.

C F Mountain.   

Abstract

When morphologically stratified, the classification of patients according to surgical stage provides an objective basis for evaluating the results of surgical treatment. In a review of 794 patients according to surgical staging criteria, the data supported concepts regarding differences in the behavior of each cell type as well as major differences in survival between each stage of disease. The overall cumulative five-year survival was 37% for squamous cell carcinoma, 27% for adenocarcinoma, and 27% for undifferentiated large cell carcinoma. Fewer than 1% of patients with undifferentiated small cell carcinoma survived. Survival for patients with surgical Stage I disease was 53%, for Stage II 29%, and for Stage III 16%. The results of surgical treatment for patients with limited disease extent are much better than is generally realized. Fifty to 60% of such patients in this series survived five years. Survival studies by surgical stage permit resonable estimates of the presence of occult metastatic disease and supply insights necessary to the design and appropriate selection of adjunctive therapeutic programs.

Entities:  

Mesh:

Year:  1977        PMID: 199119     DOI: 10.1016/s0003-4975(10)63416-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  11 in total

1.  Performance and prognosis in patients with lung cancer. The Edinburgh Lung Cancer Group.

Authors:  S Capewell; M F Sudlow
Journal:  Thorax       Date:  1990-12       Impact factor: 9.139

2.  Quantitative Proteomic Analysis of Optimal Cutting Temperature (OCT) Embedded Core-Needle Biopsy of Lung Cancer.

Authors:  Xiaozheng Zhao; Kenneth E Huffman; Junya Fujimoto; Jamie Rodriguez Canales; Luc Girard; Guangjun Nie; John V Heymach; Igacio I Wistuba; John D Minna; Yonghao Yu
Journal:  J Am Soc Mass Spectrom       Date:  2017-07-27       Impact factor: 3.109

3.  Oral administration of BCG as an adjuvant to surgical treatment of carcinoma of the bronchus.

Authors:  A B Miller; H E Taylor; M A Baker; D J Dodds; R Falk; A Frappier; D P Hill; A Jindani; S Landi; A S Macdonald; J W Thomas; C Wall
Journal:  Can Med Assoc J       Date:  1979-07-07       Impact factor: 8.262

Review 4.  The management of lung cancer.

Authors:  S G Spiro
Journal:  Lung       Date:  1982       Impact factor: 2.584

5.  Thirty years of surgery for carcinoma of the bronchus.

Authors:  J R Belcher
Journal:  Thorax       Date:  1983-06       Impact factor: 9.139

6.  Pathological assessment of mediastinal lymph nodes in lung cancer: implications for non-invasive mediastinal staging.

Authors:  K M Kerr; D Lamb; C G Wathen; W S Walker; N J Douglas
Journal:  Thorax       Date:  1992-05       Impact factor: 9.139

7.  A randomized comparison of the effects of adjuvant therapy on resected stages II and III non-small cell carcinoma of the lung. The Lung Cancel Study Group.

Authors:  E C Holmes; L D Hill; M Gail
Journal:  Ann Surg       Date:  1985-09       Impact factor: 12.969

8.  Interphase nucleolar organiser regions and survival in squamous cell carcinoma of the bronchus: a 10 year follow up study of 138 cases.

Authors:  D A Boldy; J G Ayres; J Crocker; J A Waterhouse; M Gilthorpe
Journal:  Thorax       Date:  1991-12       Impact factor: 9.139

9.  Initial clinical experience with stereotactic lung radiotherapy, based on a biological model-driven prescription method.

Authors:  C Wesley Hodge; Wolfgang A Tomé; Tracy Weigel; Anne M Traynor; Minesh P Mehta
Journal:  J Radiosurg SBRT       Date:  2011

Review 10.  Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.

Authors:  Laura Gutierrez-Sainz; Patricia Cruz-Castellanos; Oliver Higuera; Javier de Castro-Carpeño
Journal:  Curr Treat Options Oncol       Date:  2021-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.